Skip to search formSkip to main contentSkip to account menu

CPI 1189

Known as: CPI-1189 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Butanes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
CPI-1189 Protects against TNBS-induced Colitis in a Rodent Model
Nitrone-related therapeutics (NRTs) represents a new class of molecules that may be effective in treating inflammatory conditions… 
2006
2006
CPI-1189 Protects Against Dextran Sulfate Sodium-induced Colitis in Mice
Nitrone-related therapeutics (NRTs) represent a new class of small molecules potentially effective in the treatment of… 
Highly Cited
2002
Highly Cited
2002
A randomized clinical trial of CPI-1189 for HIV-associated cognitive–motor impairment
Background: CPI-1189 is a compound with antioxidant properties that blocks tumor necrosis factor-α (TNFα) effects in animal… 
Review
2002
Review
2002
CPI-1189. Centaur.
The efficacy of the proapoptotic cytokine tumor necrosis factor (TNF) alpha-inhibiting compound CPI-1189 has been demonstrated in… 
Review
2002
Review
2002
Gateways to Clinical Trials. June 2002.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2001
2001
CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation
2000
2000
CPI-1189 inhibits interleukin 1β-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties?
1998
1998
Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia 1 Published on the World Wide Web on 24 April 1998. 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)